She has earned a Master's degree in Medicine and a Doctorate in Immunology. Over the years, she has accumulated extensive clinical and research experience in pediatric hematology, especially in exploratory research on CAR-T cell immunotherapy for pediatric leukemia. She is dedicated to the stratified treatment of CAR-T, optimizing the management of complications during CAR-T therapy, and establishing a system for monitoring the effectiveness of CAR-T therapy post-treatment. Since 2015, she has been involved in CAR-T cell clinical trials, treating over 200 children annually with refractory and relapsed lymphoblastic leukemia through CAR-T therapy, achieving internationally advanced therapeutic effects. Her work on CD7 CAR-T, CD19 CAR-T, CD22 CAR-T, and sequential CD19-22 CAR-T studies has been published in authoritative international hematology journals such as Lancet oncology, JCO, Blood, JHO and Leukemia . Additionally, she has frequently reported the latest advancements in team immunotherapy at both domestic and international academic conferences, including the American Society of Clinical Oncology (ASCO), the American Society of Hematology Annual Meeting (ASH), the European Hematology Association Annual Meeting (EHA), and the Japanese Society of Hematology (JSH) meeting.